Similar to its role as a potential biomarker for poor outcomes in TAS-102 treatment of CRC, this study demonstrates that the KRAS G12 mutation can also serve as a biomarker when TAS-102 is combined with bevacizumab. The gene discussed is KRAS; the disease is colorectal carcinoma.